2026-04-14T03:26:04Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1265532025-12-04T21:12:45Zcom_2072_1057col_2072_478781col_2072_478917

00925njm 22002777a 4500 dc Armentero, Marie Therese author Pinna, Annalisa author Ferré, Sergi author Lanciego, José Luis author Müller, Christa E. author Franco Fernández, Rafael author 2018-11-28T16:54:23Z 2018-11-28T16:54:23Z 2011-12 2018-11-28T16:54:23Z Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market. The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia. At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients. However, a considerable body of data indicates that in addition to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration. Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community. Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors. Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs. Adenosina Malaltia de Parkinson Receptors cel·lulars Adenosine Parkinson's disease Cell receptors Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease